<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Pain</journal-id><journal-title>Molecular Pain</journal-title><issn pub-type="epub">1744-8069</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1744-8069-5-13</article-id><article-id pub-id-type="pmid">19291302</article-id><article-id pub-id-type="doi">10.1186/1744-8069-5-13</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Characterization of NF-kB-mediated inhibition of catechol-<italic>O</italic>-methyltransferase</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Tchivileva</surname><given-names>Inna E</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>tchivilei@dentistry.unc.edu</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Nackley</surname><given-names>Andrea G</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>andrea_neely@dentistry.unc.edu</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Qian</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>qianl2@niehs.nih.gov</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Wentworth</surname><given-names>Sean</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>sean_wentworth@dentistry.unc.edu</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Conrad</surname><given-names>Matthew</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>matthew_conrad@dentistry.unc.edu</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Diatchenko</surname><given-names>Luda B</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>lbdiatch@email.unc.edu</email></contrib></contrib-group><aff id="I1"><label>1</label>Center for Neurosensory Disorders, School of Dentistry, University of North Carolina, Chapel Hill, NC 27599-7455, USA</aff><aff id="I2"><label>2</label>Comprehensive Center for Inflammatory Disorders, School of Dentistry, University of North Carolina, Chapel Hill, NC 27599-7455, USA</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>16</day><month>3</month><year>2009</year></pub-date><volume>5</volume><fpage>13</fpage><lpage>13</lpage><ext-link ext-link-type="uri" xlink:href="http://www.molecularpain.com/content/5/1/13"/><history><date date-type="received"><day>23</day><month>1</month><year>2009</year></date><date date-type="accepted"><day>16</day><month>3</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Tchivileva et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Tchivileva et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Tchivileva E Inna tchivilei@dentistry.unc.edu </dc:author><dc:title> Characterization of NF-kB-mediated inhibition of catechol-O-methyltransferase </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>Molecular Pain 5(1): 13-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1744-8069(2009)5:1&#x0003c;13&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1744-8069</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Catechol-<italic>O</italic>-methyltransferase (COMT), an enzyme that metabolizes catecholamines, has recently been implicated in the modulation of pain. Specifically, low COMT activity is associated with heightened pain perception and development of musculoskeletal pain in humans as well as increased experimental pain sensitivity in rodents.</p></sec><sec><title>Results</title><p>We report that the proinflammatory cytokine tumor necrosis factor &#x003b1; (TNF&#x003b1;) downregulates COMT mRNA and protein in astrocytes. Examination of the distal <italic>COMT </italic>promoter <italic>(P2-COMT) </italic>reveals a putative binding site for nuclear factor &#x003ba;B (NF-&#x003ba;B), the pivotal regulator of inflammation and the target of TNF&#x003b1;. Cell culture assays and functional deletion analyses of the cloned <italic>P2-COMT </italic>promoter demonstrate that TNF&#x003b1; inhibits <italic>P2-COMT </italic>activity in astrocytes by inducing NF-&#x003ba;B complex recruitment to the specific &#x003ba;B binding site.</p></sec><sec><title>Conclusion</title><p>Collectively, our findings provide the first evidence for NF-&#x003ba;B-mediated inhibition of COMT expression in the central nervous system, suggesting that COMT contributes to the pathogenesis of inflammatory pain states.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Catechol-<italic>O</italic>-methyltransferase (COMT) metabolizes catecholamines and thereby acts as a key modulator of dopaminergic and adrenergic/noradrenergic neurotransmission [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. Converging lines of evidence have revealed an important role of COMT in the etiology and pathogenesis of a wide variety of central nervous system (CNS) disorders [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B4">4</xref>]. Recently, COMT has also been implicated in the regulation of pain perception [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. Myofacial pain patients exhibit lower COMT activity relative to controls [<xref ref-type="bibr" rid="B7">7</xref>], and COMT inhibition increases pain sensitivity in rodents by promoting catecholamine stimulation of &#x003b2;<sub>2</sub>- and &#x003b2;<sub>3</sub>-adrenergic receptors [<xref ref-type="bibr" rid="B8">8</xref>].</p><p>The COMT protein exists in two major forms: a shorter soluble form (S-COMT) and a longer membrane-bound form (MB-COMT). They are encoded from one gene by two mRNA transcripts (1.3 and 1.5 kb in human, 1.6 and 1.9 kb in rats) regulated by the proximal <italic>P1 </italic>and distal <italic>P2 </italic>promoters, respectively [<xref ref-type="bibr" rid="B9">9</xref>-<xref ref-type="bibr" rid="B11">11</xref>]. Only the longer transcript was found in the brain [<xref ref-type="bibr" rid="B12">12</xref>] with the predominant protein being MB-COMT. However, S-COMT protein is also expressed in the brain from the longer MB-COMT mRNA isoform <italic>via </italic>a leaky scanning mechanism [<xref ref-type="bibr" rid="B13">13</xref>]. Though their sequences are largely homologous, MB-COMT has approximately a 10-fold greater affinity for dopamine and noradrenaline relative to S-COMT [<xref ref-type="bibr" rid="B14">14</xref>]. Seven novel COMT mRNA variants have also been detected in brain, however, they likely to exist at much lower levels than the primary transcript [<xref ref-type="bibr" rid="B15">15</xref>]. Although recent reports describe a neuronal expression of COMT [<xref ref-type="bibr" rid="B16">16</xref>], it is primarily considered a glial enzyme [<xref ref-type="bibr" rid="B17">17</xref>-<xref ref-type="bibr" rid="B19">19</xref>].</p><p>A significant role for glia in mediating pain has been implicated by studies of patients with persistent pain conditions and animal models of pain [<xref ref-type="bibr" rid="B20">20</xref>-<xref ref-type="bibr" rid="B22">22</xref>]. Proinflammatory cytokines are produced and released by activated microglia and astrocytes in the CNS as well as by immune cells at the site of injury or inflammation. [<xref ref-type="bibr" rid="B23">23</xref>-<xref ref-type="bibr" rid="B26">26</xref>]. TNF&#x003b1; is widely considered to be the prototypic proinflammatory cytokine due to its principal role in initiating the cascade of cytokines and growth factors involved in the inflammatory response [<xref ref-type="bibr" rid="B20">20</xref>]. Tissue levels of TNF&#x003b1; have been correlated with pain report in a number of painful diseases [<xref ref-type="bibr" rid="B27">27</xref>-<xref ref-type="bibr" rid="B29">29</xref>]. TNF&#x003b1; activates NF-&#x003ba;B, which is the pivotal regulator of cellular inflammatory responses [<xref ref-type="bibr" rid="B30">30</xref>-<xref ref-type="bibr" rid="B32">32</xref>]. Specifically, the NF-&#x003ba;B pathway plays one of the major roles in injury or inflammation-evoked activation of astrocytes [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B34">34</xref>]. Within the nervous system, NF-&#x003ba;B is most frequently composed of two DNA-binding subunits (p65/Rel A and p50) that form a complex with the inhibitory subunit I&#x003ba;B which normally retains NF-&#x003ba;B within the cytoplasm of unstimulated cells [<xref ref-type="bibr" rid="B35">35</xref>]. Signal-induced phosphorylation, ubiquitination, and degradation of I&#x003ba;B triggers NF-&#x003ba;B nuclear translocation and DNA binding. Phosphorylation of I&#x003ba;B is mediated by the I&#x003ba;B kinase (IKK) complex, which consists of two catalytic subunits, IKK&#x003b1; and IKK&#x003b2;, and the regulatory subunit IKK&#x003b3; [<xref ref-type="bibr" rid="B36">36</xref>]. Gene knock-out studies have established an essential role for IKK&#x003b2; in TNF&#x003b1;-induced activation of NF-&#x003ba;B [<xref ref-type="bibr" rid="B37">37</xref>].</p><p>A growing number of reports reveal a crucial role of NF-&#x003ba;B in nociception. NF-&#x003ba;B activity is increased in animal models of neuropathic and inflammatory pain [<xref ref-type="bibr" rid="B38">38</xref>-<xref ref-type="bibr" rid="B42">42</xref>]. A specific IKK inhibitor reverses heightened pain sensitivity to noxious (hyperalgesia) and normally innocuous stimuli (allodynia) [<xref ref-type="bibr" rid="B43">43</xref>]. Increased neuropathic and inflammatory pain is suppressed by pretreatment with an NF-&#x003ba;B inhibitor [<xref ref-type="bibr" rid="B39">39</xref>,<xref ref-type="bibr" rid="B44">44</xref>]. Interestingly, selective inactivation of NF-&#x003ba;B in glial cells or astrocytes leads to decreased pain and better functional recovery [<xref ref-type="bibr" rid="B45">45</xref>-<xref ref-type="bibr" rid="B47">47</xref>].</p><p>Despite increasing evidence for an important role of NF-&#x003ba;B in pain regulation, very few studies have addressed the mechanisms whereby this pathway exerts its effects on nociception [<xref ref-type="bibr" rid="B38">38</xref>,<xref ref-type="bibr" rid="B39">39</xref>,<xref ref-type="bibr" rid="B41">41</xref>,<xref ref-type="bibr" rid="B43">43</xref>,<xref ref-type="bibr" rid="B48">48</xref>]. We hypothesized that NF-&#x003ba;B regulates expression of COMT, an enzyme known to contribute to enhanced pain states. Thus, the present study explored the relationship between the NF-&#x003ba;B pathway and COMT expression in order to gain an understanding of the cellular mechanisms underlying inflammatory pain.</p></sec><sec><title>Results</title><sec><title>TNF&#x003b1; inhibits endogenous COMT expression in astrocytes</title><p>To elucidate a potential role of TNF&#x003b1; in regulating COMT expression, we treated rat primary astrocytes with TNF&#x003b1; and measured COMT protein levels using Western blot analysis. A significant reduction in COMT protein expression was observed beginning at 8 h (Figure <xref ref-type="fig" rid="F1">1A</xref>) with a 60% maximal decrease relative to untreated control (<italic>P </italic>&#x0003c; 0.05; Figure <xref ref-type="fig" rid="F1">1B</xref>). Using quantitative real-time RT-PCR analysis, we further demonstrated a down-regulation of MB-COMT mRNA at 0.5 h and 30 h following TNF&#x003b1; treatment (<italic>P </italic>&#x0003c; 0.01; Figure <xref ref-type="fig" rid="F1">1C</xref>). This oscillatory rather than linear pattern of MB-COMT mRNA expression is in agreement with previously reported characteristics of NF-kB-mediated gene regulation and has been associated with autoregulation of NF-&#x003ba;B activity, as one of the genes activated by NF-&#x003ba;B is that encoding its own inhibitor, I&#x003ba;B&#x003b1; [<xref ref-type="bibr" rid="B49">49</xref>]. Finally, a dye exclusion test verified that the TNF&#x003b1;-dependent down-regulation of COMT was not due to cytotoxic effects as more than 95% of cells treated with TNF&#x003b1; remained viable (data not shown).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>COMT expression is downregulated by TNF&#x003b1; in primary astrocytes</bold>. Administration of TNF&#x003b1; (20 ng/ml) decreases COMT protein expression in primary astrocytes as indicated by (A) a representative Western blot and (B) quantitative analysis of Western blots from experiments performed in triplicate. (C) Administration of TNF&#x003b1; (20 ng/ml) also decreases MB-COMT mRNA expression in primary astrocytes. Data are Means &#x000b1; SEM. *<italic>P </italic>&#x0003c; 0.05 and **<italic>P </italic>&#x0003c; 0.01 different from untreated control.</p></caption><graphic xlink:href="1744-8069-5-13-1"/></fig></sec><sec><title>Cloning and structural analysis of the human distal <italic>COMT </italic>promoter</title><p>To study the signaling mechanisms whereby TNF&#x003b1; regulates COMT expression, we cloned the human distal <italic>COMT </italic>promoter <italic>(P2-COMT) </italic>which controls transcription of MB-COMT mRNA (Figure <xref ref-type="fig" rid="F2">2A</xref>). A 1.5 kb DNA fragment corresponding to the previously published <italic>P2-COMT </italic>sequences [GenBank: <ext-link ext-link-type="gen" xlink:href="Z26490">Z26490</ext-link> and <ext-link ext-link-type="gen" xlink:href="AF001102">AF001102</ext-link>] [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B50">50</xref>] was cloned in the pGL3 luciferase reporter vector. Using TFSearch database [<xref ref-type="bibr" rid="B51">51</xref>], we analyzed the cloned sequence and identified a number of potential transcription factor binding elements that can affect both constitutive and tissue-specific expression of COMT gene, such as TATA and CAAT boxes, CRE, C/EBP, and NF-&#x003ba;B sites. The presence of the NF-&#x003ba;B consensus binding site 5'-GGGGACGCCC-3' at position -109 from the first transcription initiation site of MB-COMT indicated that this promoter could be regulated by NF-&#x003ba;B pathway and respond to TNF&#x003b1; treatment.</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Activity of <italic>P2-COMT </italic>promoter is downregulated by TNF&#x003b1; in H4 astroglial cells</bold>. (A) Schematic diagram of human <italic>COMT </italic>gene. The exon-intron organization is not to scale. The positions of translation start codons for MB-COMT (MB-ATG) and S-COMT (S-ATG) polypeptides, translation stop codon (TGA), putative polyadenylation signal (AATTAA), promoter regions, and primers (U1 and D1) are shown. (B) Administration of TNF&#x003b1; (20 ng/ml) inhibits activity of transfected <italic>P2-COMT/Luc </italic>reporter in H4 but not in H4 I&#x003ba;B&#x003b1;-SR cells. Data are Means &#x000b1; SEM. *<italic>P </italic>&#x0003c; 0.05, ***<italic>P </italic>&#x0003c; 0.001 H4 different from H4 I&#x003ba;B&#x003b1;-SR cells at 16 and 24 h, respectively. (C) TNF&#x003b1;-mediated inhibition is specific to <italic>P2-COMT </italic>promoter. The activity of <italic>3x-&#x003ba;B/Luc </italic>reporter (&#x003ba;B consensus sites from the MHC class I promoter) was tested after treatment with TNF&#x003b1; (20 ng/ml) for 24 h. *<italic>P </italic>&#x0003c; 0.05 different from untreated control.</p></caption><graphic xlink:href="1744-8069-5-13-2"/></fig></sec><sec><title>COMT inhibition by TNF&#x003b1; requires NF-&#x003ba;B activation</title><p>Luciferase reporter gene assays were employed to test the effect of TNF&#x003b1; treatment on <italic>P2-COMT </italic>activity. A chimeric human <italic>P2-COMT/Luc </italic>construct was transiently transfected into human H4 astroglioma cells. Consistent with the observed down-regulation of endogenous COMT expression, TNF&#x003b1; treatment decreased <italic>P2-COMT </italic>activity in time-dependent manner. After a 24-hour incubation with TNF&#x003b1;, <italic>P2-COMT </italic>activity was reduced to 60% relative to untreated control (<italic>P </italic>&#x0003c; 0.05 and <italic>P </italic>&#x0003c; 0.001 at 16 h and 24 h, respectively; Figure <xref ref-type="fig" rid="F2">2B</xref>). To test if the TNF&#x003b1;-mediated inhibition of <italic>P2-COMT </italic>activity requires NF-&#x003ba;B pathway activation, H4 astroglial cells stably transfected with I&#x003ba;B&#x003b1; super-repressor (SR), a nondegradable dominant-negative inhibitor of all NF-&#x003ba;B complexes, were transiently transfected with <italic>P2-COMT/Luc </italic>construct and <italic>P2-COMT </italic>activity was measured during 24 h of TNF&#x003b1; treatment. H4 I&#x003ba;B&#x003b1;-SR cells were no longer sensitive to TNF&#x003b1;-mediated inhibition of <italic>P2-COMT </italic>activity (Figure <xref ref-type="fig" rid="F2">2B</xref>).</p><p>As NF-&#x003ba;B is generally recognized as a positive regulator of gene expression, we used a reporter vector with a promoter known to be up-regulated in response to NF-&#x003ba;B activation. A luciferase reporter vector containing &#x003ba;B consensus sites from the MHC class I promoter was transfected into H4 astroglioma cells. After treatment with TNF&#x003b1;, the MHC promoter reporter showed a 14-fold increase in expression, demonstrating that the TNF&#x003b1;-mediated inhibition of COMT expression in astroglioma cells is <italic>P2-COMT </italic>promoter specific (<italic>P </italic>&#x0003c; 0.05; Figure <xref ref-type="fig" rid="F2">2C</xref>).</p><p>Finally, to test effect of NF-&#x003ba;B pathway on endogenous COMT expression, we also treated H4 I&#x003ba;B&#x003b1;-SR cells with TNF&#x003b1;. Consistent with reporter assay results, TNF&#x003b1; was unable to significantly repress endogenous COMT protein and mRNA levels in H4 I&#x003ba;B&#x003b1;-SR cells (<italic>P </italic>&#x0003e; 0.05 for protein level and <italic>P </italic>&#x0003e; 0.05 for mRNA; Figure <xref ref-type="fig" rid="F3">3A, B</xref>, and <xref ref-type="fig" rid="F3">3C</xref>).</p><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>TNF&#x003b1;-mediated repression of COMT is attenuated in H4 I&#x003ba;B&#x003b1;-SR astroglial cells</bold>. Administration of TNF&#x003b1; (100 ng/ml) does not reduce COMT expression in H4 I&#x003ba;B&#x003b1;-SR cells as indicated by (A) a representative Western blot, (B) quantitative analysis of Western blots from experiments performed in triplicate, and (C) quantitative real-time RT-PCR analysis of MB-COMT mRNA. <italic>P </italic>&#x0003e; 0.05 different from untreated control.</p></caption><graphic xlink:href="1744-8069-5-13-3"/></fig></sec><sec><title>TNF&#x003b1; inhibits COMT <italic>via </italic>a canonical NF-&#x003ba;B activation mechanism</title><p>As TNF&#x003b1; may function <italic>via </italic>NF-&#x003ba;B and JUN N-terminal kinase (JNK) signaling cascades [<xref ref-type="bibr" rid="B52">52</xref>], we sought to determine whether a signal that elicits NF-&#x003ba;B activation alone would repress <italic>COMT </italic>gene expression. Thus, we tested if overexpression of p65 or IKK&#x003b2;, which are both essential for NF-&#x003ba;B activation, would negatively regulate <italic>P2-COMT </italic>activity. Our data demonstrate that p65 or IKK&#x003b2; overexpression dramatically decreases <italic>P2-COMT </italic>activity (<italic>P </italic>&#x0003c; 0.01; Figure <xref ref-type="fig" rid="F4">4A</xref>).</p><fig position="float" id="F4"><label>Figure 4</label><caption><p><bold>NF-&#x003ba;B is required for COMT downregulation</bold>. (A) Cotransfection of pCMV-SPORT-M-p65 or pCMV-SPORT-M-IKK&#x003b2; inhibits <italic>P2-COMT/Luc </italic>reporter activity in H4 cells. Data are Means &#x000b1; SEM. **<italic>P </italic>&#x0003c; 0.01 different from <italic>P2-COMT/Luc </italic>alone. Western blot analysis was performed with protein extracts from H4 cells treated with TNF&#x003b1; (20 ng/ml) for the indicated timepoints. Expression of I&#x003ba;B&#x003b1; was evaluated in cytoplasmic fraction of H4 cells (B), whereas p65 and p50 protein levels were tested in nuclear extracts (C).</p></caption><graphic xlink:href="1744-8069-5-13-4"/></fig><p>Next, we examined whether TNF&#x003b1; engaged the canonical mechanism of I&#x003ba;B&#x003b1; phosphorylation and degradation to trigger transport of NF-&#x003ba;B to the nucleus in our experimental conditions. H4 cells were treated with TNF&#x003b1; and then cytoplasmic and nuclear extracts analyzed by Western blot. The degradation of I&#x003ba;B&#x003b1; in the cytoplasmic fraction of the cells and simultaneous increase in the nuclear level of p65 was observed at 30 min (Figure <xref ref-type="fig" rid="F4">4B</xref> and <xref ref-type="fig" rid="F4">4C</xref>), characteristic of dynamic NF-&#x003ba;B signaling [<xref ref-type="bibr" rid="B53">53</xref>]. Together, these results demonstrate that TNF&#x003b1; initiates the canonical I&#x003ba;B&#x003b1; degradation pathway to activate NF-&#x003ba;B in H4 astroglioma cells, and that NF-&#x003ba;B activation inhibits COMT in glial cells.</p></sec><sec><title>Identification of the functional NF-&#x003ba;B binding site in the <italic>P2-COMT </italic>promoter</title><p>To identify the NF-&#x003ba;B-responsive region in the <italic>P2-COMT </italic>promoter, we analyzed the activity of serial 5'deletions of the <italic>P2-COMT/Luc </italic>constructs transiently transfected into H4 or H4 I&#x003ba;B&#x003b1;-SR cells (Fig. <xref ref-type="fig" rid="F5">5A</xref>). Consequent deletions of 5'fragments led to a graduate increase in overall basal promoter activity in all constructs, suggesting the presence of serial putative negatively regulating elements along the <italic>P2-COMT </italic>promoter. <italic>Del.2 </italic>construct that lack the putative &#x003ba;B consensus binding site also showed a lack of response to TNF&#x003b1; treatment in either H4 or H4 I&#x003ba;B&#x003b1;-SR cells (<italic>P </italic>&#x0003e; 0.05; Figure <xref ref-type="fig" rid="F5">5B</xref> and <xref ref-type="fig" rid="F5">5C</xref>). Conversely, TNF&#x003b1; treatment of H4 but not H4 I&#x003ba;B&#x003b1;-SR cells inhibited activity of construct <italic>Del.1 </italic>containing the putative &#x003ba;B consensus binding site and the initial <italic>P2-COMT </italic>promoter construct (<italic>P </italic>&#x0003c; 0.05 for H4 cells and <italic>P </italic>&#x0003e; 0.05 for H4 I&#x003ba;B&#x003b1;-SR cells; Figure <xref ref-type="fig" rid="F5">5B</xref> and <xref ref-type="fig" rid="F5">5C</xref>). Thus, the region between position -155 and -33 appears to be crucial for TNF&#x003b1;-dependent suppression of <italic>P2-COMT </italic>activity.</p><fig position="float" id="F5"><label>Figure 5</label><caption><p><bold>Identification of TNF&#x003b1;-responsive region in the <italic>P2-COMT </italic>promoter</bold>. (A) Schematic diagram of the <italic>P2-COMT/Luc </italic>construct and its serial deletions <italic>Del.1 </italic>and <italic>Del.2</italic>. The effect of TNF&#x003b1; (20 ng/ml, 8 h of treatment) on the relative activity of the <italic>P2-COMT/Luc, Del.1 </italic>and <italic>Del.2 </italic>constructs transfected into H4 (B) and H4 I&#x003ba;B&#x003b1;-SR (C) cells. Data are Means &#x000b1; SEM. *<italic>P </italic>&#x0003c; 0.05 different from untreated control. (D) Binding of p65 to a plate-immobilized oligonucleotide containing a &#x003ba;B binding site was measured by TransAM NF-&#x003ba;B assay in the nuclear extracts from H4 cells 30 min post TNF&#x003b1; treatment. This activation was prevented by competition with a wild-type binding control (WT BC) &#x003ba;B consensus oligonucleotide or a wild-type <italic>P2-COMT </italic>&#x003ba;B consensus oligonucleotide (WT P2). Oligonucleotides with mutated &#x003ba;B binding sites &#x02013; a mutant binding control (MT BC) and a mutant <italic>P2-COMT </italic>(MT P2-COMT) &#x02013; had little or no effect. Data are Means &#x000b1; SEM. <sup>###</sup><italic>P </italic>&#x0003c; 0.001 TNF&#x003b1;-treated different from untreated control, ***<italic>P </italic>&#x0003c; 0.001 TNF&#x003b1;-treated different from TNF&#x003b1;+WT BC and WT P2 oligos, *<italic>P </italic>&#x0003c; 0.05 TNF&#x003b1;-treated different from TNF&#x003b1;+MT BC oligo.</p></caption><graphic xlink:href="1744-8069-5-13-5"/></fig><p>To determine whether TNF&#x003b1; induces NF-&#x003ba;B binding to the consensus DNA site of the identified region, we used ELISA to detect bound NF-&#x003ba;B p65 subunits. This method was employed as an alternative to the electrophoretic mobility shift assay, as it was reported to be more sensitive and quantitative [<xref ref-type="bibr" rid="B54">54</xref>]. DNA binding of p65 was dramatically increased in nuclear extracts of H4 cells after 30 min of TNF&#x003b1; treatment (<italic>P </italic>&#x0003c; 0.001; Figure <xref ref-type="fig" rid="F5">5D</xref>). This binding was abrogated by incubation of the nuclear extracts with either a competing control wild-type &#x003ba;B consensus oligonucleotide (Figure <xref ref-type="fig" rid="F5">5D</xref>, WT BC oligo) or with a competing oligonucleotide containing a wild-type putative &#x003ba;B binding sequence 5'-G<underline>GGG</underline>ACGCCC-3' at position -109 in the <italic>P2-COMT </italic>promoter (Figure <xref ref-type="fig" rid="F5">5D</xref>, WT P2 oligo). Conversely, both oligonucleotides containing either a mutated version of the control &#x003ba;B consensus sequence (Figure <xref ref-type="fig" rid="F5">5D</xref>, MT BC oligo) or a mutated sequence 5'-G<underline>CTC</underline>ACGCCC-3' of the putative &#x003ba;B binding site of the <italic>P2-COMT </italic>promoter (Figure <xref ref-type="fig" rid="F5">5D</xref>, MT P2 oligo) had a minimal effect on TNF&#x003b1;-induced p65 binding. Results from these experiments confirm that TNF&#x003b1; induces p65 recruitment to the functional &#x003ba;B binding site at position -109 in the <italic>P2-COMT </italic>promoter.</p></sec></sec><sec><title>Discussion</title><p>In the present report, we provide the first demonstration that <italic>COMT </italic>gene expression is downregulated by TNF&#x003b1; in primary rat astrocytes at both protein and mRNA levels. As the <italic>P2-COMT </italic>promoter controls expression of MB-COMT, the main COMT transcript in brain, this promoter was cloned from human genomic DNA and transfected in H4 astroglioma cells. The activity of the cloned promoter was substantially suppressed by TNF&#x003b1; in a time-dependent manner.</p><p>A number of putative regulatory elements have been described in <italic>P1</italic>- and <italic>P2-COMT </italic>promoters, including estrogen response (ER) elements [<xref ref-type="bibr" rid="B50">50</xref>] that likely mediate estradiol-dependent downregulation of COMT expression in cell culture [<xref ref-type="bibr" rid="B55">55</xref>]. <italic>P2-COMT </italic>also contains abundant methylation sites associated with cancer development [<xref ref-type="bibr" rid="B56">56</xref>], schizophrenia, and bipolar disorder [<xref ref-type="bibr" rid="B57">57</xref>]. We identified a novel putative regulatory site &#x02013; a &#x003ba;B consensus sequence that is a potential target for TNF&#x003b1;-dependent NF-&#x003ba;B activation.</p><p>Next, we demonstrated that TNF&#x003b1;-dependent COMT downregulation was indeed mediated by the NF-&#x003ba;B pathway. Transient expression of p65, the essential component of NF-&#x003ba;B complexes, or IKK&#x003b2;, the major positive regulator of NF-&#x003ba;B activition, significantly decreased <italic>P2-COMT </italic>reporter expression. In addition, H4 I&#x003ba;B&#x003b1;-SR cells lost the ability to regulate <italic>P2-COMT </italic>promoter expression in response to TNF&#x003b1; treatment. The TNF&#x003b1;-mediated suppression of endogenous COMT expression was also abrogated in H4 I&#x003ba;B&#x003b1;-SR cells. Moreover, we confirmed that TNF&#x003b1; activated NF-&#x003ba;B in H4 astroglioma cells through the canonical I&#x003ba;B degradation pathway to trigger p65 nuclear translocation and DNA binding.</p><p>Our data strongly suggest that the putative &#x003ba;B binding site 5'-GGGGACGCCC-3' at position -109 of the <italic>P2-COMT </italic>promoter region is a functional site for NF-&#x003ba;B-mediated regulation of COMT expression as deletion of the <italic>P2-COMT </italic>region containing this site abrogated TNF&#x003b1;-dependent inhibition of <italic>P2-COMT </italic>activity in H4 astroglioma cells. Furthermore, competition experiments performed with the wild type or mutant site-specific oligonucleotides showed that TNF&#x003b1; indeed induced recruitment of p65 to this &#x003ba;B consensus binding site of the promoter.</p><p>Although NF-&#x003ba;B-mediated activation of transcription is well known, the mechanisms of NF-&#x003ba;B-mediated repression are poorly established. Probably, the best studied example of transcriptional repression by NF-&#x003ba;B complex is described for Dorsal transcription factor, a <italic>Drosophila </italic>Rel family member that can either activate or repress gene expression through the recruitment of coactivators such as CBP or corepressors such as Groucho [<xref ref-type="bibr" rid="B58">58</xref>]. Furthermore, a number of examples have been reported in mammals. NF-&#x003ba;B can repress transcription by competing with steroid receptors for a common promoter <italic>cis</italic>-DNA element [<xref ref-type="bibr" rid="B59">59</xref>]<italic>via </italic>N-myc recruitment to the glutamate transporter gene promoter [<xref ref-type="bibr" rid="B53">53</xref>] and through inhibiting histone H4 acetylation at the cytochrome P-450 1A1 promoter [<xref ref-type="bibr" rid="B60">60</xref>]. Thus, further experiments should be conducted to address the specific mechanism underlying NF-&#x003ba;B-dependent inhibition of <italic>COMT </italic>gene expression. Interestingly, consequent deletions of 5'fragments of the <italic>P2-COMT </italic>promoter led to a significant increase in overall basal promoter activity. This result would suggest the presence of a number of putative negatively regulating elements along the <italic>P2-COMT </italic>promoter other than ER- and &#x003ba;B-response elements. Although, to date, no studies have systematically searched for regulators of COMT expression, this finding clearly warrants further research.</p><p>Our results demonstrating that COMT expression is downregulated in astrocytes under inflammatory conditions are in line with those of other studies showing a positive correlation between astrocyte activation and exaggerated pain responses [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B61">61</xref>]. Intrathecal injection of gp120 (human immunodeficiency virus-1 envelope glycoprotein) induces mechanical allodynia <italic>via </italic>the release of proinflammatory cytokines and NF-&#x003ba;B activation in spinal cord astrocytes, but not in microglial cells or neurons [<xref ref-type="bibr" rid="B62">62</xref>]. Selective inactivation of astroglial NF-&#x003ba;B in transgenic mice expressing a dominant negative form of the inhibitor I&#x003ba;B&#x003b1; leads to a dramatic improvement in functional recovery after contusive spinal cord injury (SCI) [<xref ref-type="bibr" rid="B46">46</xref>] and decreases formalin-induced pain [<xref ref-type="bibr" rid="B47">47</xref>]. Additionally, several recent studies report cell type-specific NF-&#x003ba;B activation by cytokines. For example, in rat brain cultures IL-1 induces NF-&#x003ba;B activation in astrocytes, but not in neurons [<xref ref-type="bibr" rid="B63">63</xref>,<xref ref-type="bibr" rid="B64">64</xref>]. Taken together, these studies unequivocally link NF-&#x003ba;B activation in astrocytes to pain states.</p><p>Although activation of the NF-&#x003ba;B pathway has been deemed critical for the development of pain [<xref ref-type="bibr" rid="B40">40</xref>-<xref ref-type="bibr" rid="B42">42</xref>], there are few reports studying NF-kB-dependent pro-nociceptive signaling. Historically, these studies have focused on NF-kB-dependent up-regulation of pro-inflammatory cytokines [<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B65">65</xref>], cyclooxygenase-2 (COX-2) [<xref ref-type="bibr" rid="B39">39</xref>,<xref ref-type="bibr" rid="B43">43</xref>], inducible and neuronal nitric oxide synthases (iNOS and nNOS) [<xref ref-type="bibr" rid="B38">38</xref>,<xref ref-type="bibr" rid="B41">41</xref>], c-src [<xref ref-type="bibr" rid="B48">48</xref>], and c-fos [<xref ref-type="bibr" rid="B38">38</xref>]. However, recent studies from our group demonstrated that genetic variants of <italic>COMT </italic>coding for low enzymatic activity are associated with heightened experimental pain sensitivity and the onset of a myofacial pain condition in humans [<xref ref-type="bibr" rid="B5">5</xref>]. Additionally, pharmacologic inhibition of COMT in a rat model of inflammation resulted in elevated pain sensitivity [<xref ref-type="bibr" rid="B8">8</xref>]. Together, these data suggest that an NF-&#x003ba;B-mediated decrease in COMT expression is likely to contribute to heightened pain sensitivity under inflammatory conditions. A series of <italic>in vivo </italic>experiments further addressing this hypothesis are currently being conducted in our laboratory.</p></sec><sec><title>Conclusion</title><p>Collectively, our results provide the first evidence that COMT expression is downregulated in astrocytes <italic>via </italic>recruitment of the NF-&#x003ba;B complex to a specific &#x003ba;B-site at the <italic>P2-COMT </italic>promoter. NF-&#x003ba;B-mediated inhibition of COMT in the CNS may represent a novel mechanism contributing to inflammatory pain. NF-&#x003ba;B is regarded as one of the most important targets for therapeutic intervention against inflammatory conditions [<xref ref-type="bibr" rid="B66">66</xref>,<xref ref-type="bibr" rid="B67">67</xref>]; thus, elucidating the cellular mechanisms that underlie NF-&#x003ba;B-mediated inflammatory pain will promote the development of novel therapies including pharmacologic agents that block COMT-dependent pain signaling.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Cell culture and reagents</title><p>Primary astrocytes were isolated and cultured as described earlier [<xref ref-type="bibr" rid="B68">68</xref>]. Human H4 astroglioma cells were obtained from ATCC (HTB-148) and cultured in DMEM (Sigma), 10% fetal bovine serum (FBS; HyClone) and 1&#x000d7; penicillin-streptomycin (Invitrogen). H4 cells stably expressing I&#x003ba;B&#x003b1;-SR were a generous gift from Dr. Baldwin (UNC) and generated as described previously [<xref ref-type="bibr" rid="B53">53</xref>]. All oligonucleotides were obtained from MWG-Biotech AG. The pCMV-SPORT-M, pCMV-SPORT-M-p65 and pCMV-SPORT-M-IKK&#x003b2; expression vectors were a generous gift provided by Dr. Romanov (Attagene) and 3x-&#x003ba;B/luc construct was a gift from Dr. Baldwin (UNC).</p></sec><sec><title>Quantitative real-time RT-PCR</title><p>Total RNA was isolated using the Trizol reagent (Invitrogen), treated with RNase free-DNase I (Promega) and reverse transcribed with random primers by Superscript III (Invitrogen). The cDNA was amplified with SYBR Green PCR master mix (Applied Biosystems) using forward and reverse PCR primers (5'-CCAGAGGAGACCCCAGACC-3' and 5'-ACAGCTGCCAACAGCAGAG-3', respectively, for human MB-COMT; 5'-GGAAATCGTGCGTGACATC-3' and 5'-CATGGATGCCAAGGATTC-3', for human &#x003b2;-actin; 5'-CCAGAGGAGACCCCAGACC and 5'-ACAGCTGCCAACAGCAGAG-3', for rat MB-COMT; and 5'-TGCGGGTCATAAGCTTGC-3' and 5'-CGATCCGAGGGCCTCACTA-3' for rat 18S rRNA) in S2 Real Time PCR machine (Eppendorf). PCR reactions were performed in triplicate. Three independent experiments were performed, and the result of a representative experiment is shown. MB-COMT mRNA levels were normalized to &#x003b2;-actin RNA or 18S rRNA as an endogenous control.</p></sec><sec><title>Western blot analysis</title><p>10&#x02013;50 &#x003bc;g of protein lysates from whole cells, nuclear and cytoplasmic extracts, normalized for protein content using a BCA Protein Assay Kit (Pierce), were run on precast Novex Tris-Glycine gels (Invitrogen), blotted onto nitrocellose (Whatman), and blocked in TBST with 5% nonfat dry milk. The following antibodies were used: COMT (Chemicon, AB5873), &#x003b2;-actin (I-19) (Santa Cruz, SC-1616), I&#x003ba;B&#x003b1; (C-21) (Santa Cruz, SC-371), p65 (Cell Signaling, #3034), and p50 (Santa Cruz, SC-7178). Chemiluminescence was detected in ImageQuant-ECL Imaging System (GE Healthcare) and images were analyzed using ImageQuant TL software (GE Healthcare). Blots from three independent experiments were densitometrically analysed and the values normalized to the &#x003b2;-actin control, with untreated group set to 100%.</p></sec><sec><title>Cloning of human P2-COMT distal promoter</title><p>Primers <bold>U1 </bold>5'-<underline>CCTACGCGT</underline>GCTCCTCTGGCGGAAAGGAA-3' and <bold>D1 </bold>5'-<underline>CGAAGATCT</underline>ACCTCTCCCGCGACGGCCCG-3', with added Mlu I and Bgl II restriction sites, respectively, were used to amplify <italic>P2-COMT </italic>from 50 ng of human genomic DNA with GeneAmp PCR kit (Applied Biosystems). The 1.5 kb PCR product was digested by Mlu I and Bgl II restrictases (NEB), gel-purified, ligated into pGL3 Luciferase Reporter Vector (Promega) using Rapid DNA Ligation Kit (Roche) and transformed into competent <italic>E. coli </italic>DH5&#x003b1; cells (Invitrogen). Recombinant plasmids were isolated using EndoFree Plasmid Kit (Qiagen) and sequenced at UNC sequencing facility. Putative regulatory elements were determined with TFSearch database <ext-link ext-link-type="uri" xlink:href="http://www.cbrc.jp/research/db/TFSEARCH.html"/>.</p></sec><sec><title>Construction of serial 5'-end deletions of human P2-COMT/Luc clone</title><p>Serial deletions were generated by PCR amplification of corresponding fragments from <italic>P2-COMT/Luc </italic>clone using forward primers, containing Mlu I restriction site, and reverse primers, containing Bgl II site, <bold>U2 </bold>5'-<underline>CCTACGCGT</underline>GCGGACACCCTCACGAGGACA-3' and <bold>D1</bold>, respectively, for <italic>Del. 1</italic>, and <bold>U3 </bold>5'-<underline>CCTACGCGT</underline>CCACCGGAAGCGCCCTCCTA-3' and <bold>D1 </bold>for <italic>Del. 2</italic>. The amplified fragments were digested by Mlu I and Bgl II, purified from the agarose gel and cloned into pGL3 reporter vector. Deletions were confirmed by sequencing. The nucleotide numeration was based on Tenhunen et al. [<xref ref-type="bibr" rid="B11">11</xref>].</p></sec><sec><title>Transient transfection, luciferase and &#x003b2;-galactosidase assays</title><p>Cells were seeded into 12-well plates (5 &#x000d7; 10<sup>4</sup>cells/well) and transfected with 500 ng of total DNA using FuGene 6 reagent (Roche). Normally, up to 400 ng of P2-COMT luciferase reporter and 30 ng of control plasmid for transfection efficiency (pSV-&#x003b2;-galactosidase vector, Promega) were used for transfection. The amount of DNA was kept constant by addition of pCMV-Sport-M vector with no insert. Cells were treated by TNF&#x003b1; (R&#x00026;D Systems) and harvested 48 h after transfection. Luciferase activity was determined using Luciferase Assay System (Promega) and normalized for transfection efficiency by measuring the &#x003b2;-galactosidase activity using a &#x003b2;-Galactosidase Enzyme Assay System (Promega). Transfections were performed in triplicate, and a representative experiment is shown.</p></sec><sec><title>ELISA for activated NF-&#x003ba;B</title><p>NF-&#x003ba;B activation was measured using TransAM NF-&#x003ba;B p65 Chemi Kit (Active Motif). Cell lysates were tested for their ability to bind to a plate-immobilized oligonucleotide containing a &#x003ba;B consensus binding site (5'-GGGACTTTCC-3'). Competition experiments were performed with the wild-type (ACCGC<bold>G<underline>GGG</underline>ACGCCCG<underline>GGG</underline>ACGCCC</bold>CGACC) and mutant (5'-ACCGC<bold>G</bold><underline>CTC</underline><bold>ACGCCCG<underline>CTC</underline>ACGCCC</bold>CGACC) oligonucleotides specific to <italic>P2-COMT </italic>&#x003ba;B binding site and &#x003ba;B wild-type and mutated consensus oligonucleotides provided by the manufacturer. The wild-type but not mutated oligonucleotides were expected to compete with NF-&#x003ba;B for binding. Chemiluminescence was measured in 1420 Multilabel Counter Victor3 (PerkinElmer). Nuclear extracts were prepared using Nuclear Extract Kit (Active Motif).</p></sec><sec><title>Statistical Analysis</title><p>Protein, mRNA, and promoter activity data were analyzed by paired t-test and analysis of variance (ANOVA) with post-hoc tests. <italic>P </italic>&#x0003c; 0.05 was considered to be statistically significant.</p></sec></sec><sec><title>List of abbreviations</title><p>COMT: catechol-O-methyltransferase; I&#x003ba;B&#x003b1;: inhibitory factor &#x003ba;B; IKK: I&#x003ba;B kinase; NF-&#x003ba;B: nuclear factor &#x003ba;B; TNF&#x003b1;: tumor necrosis factor &#x003b1;.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>IET and LBD conceived of the study, and IET, AGN, SW, MC, and LQ performed experiments. IET, AGN, and LBD participated in writing of the manuscript. All authors read and approved the final manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>We thank Drs. Maixner and Baldwin for helpful and inspiring discussions, Kathryn Satterfield, Brad Cooke, and Dustin Gibson for technical assistance, Dr. Sitcheran for helpful discussions and a gift of H4 I&#x003ba;B&#x003b1;-SR cell line and <italic>&#x003ba;B </italic>reporter, and Dr. Romanov for p65 and IKK&#x003b2; expression vectors. This work was supported by the NIH/NIDCR RO1 DE016558 grant to LBD and the NIH/NICHHD K12 HD052191 grant to AGN.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Axelrod</surname><given-names>J</given-names></name><name><surname>Tomchik</surname><given-names>R</given-names></name></person-group><article-title>O-methylation of catechol amines in vivo</article-title><source>J Biol Chem</source><year>1958</year><volume>233</volume><fpage>702</fpage><lpage>705</lpage><pub-id pub-id-type="pmid">13575440</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mannisto</surname><given-names>PT</given-names></name><name><surname>Kaakkola</surname><given-names>S</given-names></name></person-group><article-title>Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors</article-title><source>Pharmacol Rev</source><year>1999</year><volume>51</volume><fpage>593</fpage><lpage>628</lpage><pub-id pub-id-type="pmid">10581325</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>BT</given-names></name></person-group><article-title>Catechol-O-Methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis</article-title><source>Curr Drug Metab</source><year>2002</year><volume>3</volume><fpage>321</fpage><lpage>349</lpage><pub-id pub-id-type="pmid">12083324</pub-id><pub-id pub-id-type="doi">10.2174/1389200023337586</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tunbridge</surname><given-names>EM</given-names></name><name><surname>Harrison</surname><given-names>PJ</given-names></name><name><surname>Weinberger</surname><given-names>DR</given-names></name></person-group><article-title>Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond</article-title><source>Biol Psychiatry</source><year>2006</year><volume>60</volume><fpage>141</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">16476412</pub-id><pub-id pub-id-type="doi">10.1016/j.biopsych.2005.10.024</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diatchenko</surname><given-names>L</given-names></name><name><surname>Slade</surname><given-names>GD</given-names></name><name><surname>Nackley</surname><given-names>AG</given-names></name><name><surname>Bhalang</surname><given-names>K</given-names></name><name><surname>Sigurdsson</surname><given-names>A</given-names></name><name><surname>Belfer</surname><given-names>I</given-names></name><name><surname>Goldman</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Shabalina</surname><given-names>SA</given-names></name><name><surname>Shagin</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Genetic basis for individual variations in pain perception and the development of a chronic pain condition</article-title><source>Hum Mol Genet</source><year>2005</year><volume>14</volume><fpage>135</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">15537663</pub-id><pub-id pub-id-type="doi">10.1093/hmg/ddi013</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diatchenko</surname><given-names>L</given-names></name><name><surname>Nackley</surname><given-names>AG</given-names></name><name><surname>Slade</surname><given-names>GD</given-names></name><name><surname>Bhalang</surname><given-names>K</given-names></name><name><surname>Belfer</surname><given-names>I</given-names></name><name><surname>Max</surname><given-names>MB</given-names></name><name><surname>Goldman</surname><given-names>D</given-names></name><name><surname>Maixner</surname><given-names>W</given-names></name></person-group><article-title>Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli</article-title><source>Pain</source><year>2006</year><volume>125</volume><fpage>216</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">16837133</pub-id><pub-id pub-id-type="doi">10.1016/j.pain.2006.05.024</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marbach</surname><given-names>JJ</given-names></name><name><surname>Levitt</surname><given-names>M</given-names></name></person-group><article-title>Erythrocyte catechol-O-methyltransferase activity in facial pain patients</article-title><source>J Dent Res</source><year>1976</year><volume>55</volume><fpage>711</fpage><pub-id pub-id-type="pmid">1064628</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nackley</surname><given-names>AG</given-names></name><name><surname>Tan</surname><given-names>KS</given-names></name><name><surname>Fecho</surname><given-names>K</given-names></name><name><surname>Flood</surname><given-names>P</given-names></name><name><surname>Diatchenko</surname><given-names>L</given-names></name><name><surname>Maixner</surname><given-names>W</given-names></name></person-group><article-title>Catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both beta2- and beta3-adrenergic receptors</article-title><source>Pain</source><year>2007</year><volume>128</volume><fpage>199</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">17084978</pub-id><pub-id pub-id-type="doi">10.1016/j.pain.2006.09.022</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salminen</surname><given-names>M</given-names></name><name><surname>Lundstrom</surname><given-names>K</given-names></name><name><surname>Tilgmann</surname><given-names>C</given-names></name><name><surname>Savolainen</surname><given-names>R</given-names></name><name><surname>Kalkkinen</surname><given-names>N</given-names></name><name><surname>Ulmanen</surname><given-names>I</given-names></name></person-group><article-title>Molecular cloning and characterization of rat liver catechol-O-methyltransferase</article-title><source>Gene</source><year>1990</year><volume>93</volume><fpage>241</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">2227437</pub-id><pub-id pub-id-type="doi">10.1016/0378-1119(90)90231-F</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lundstrom</surname><given-names>K</given-names></name><name><surname>Salminen</surname><given-names>M</given-names></name><name><surname>Jalanko</surname><given-names>A</given-names></name><name><surname>Savolainen</surname><given-names>R</given-names></name><name><surname>Ulmanen</surname><given-names>I</given-names></name></person-group><article-title>Cloning and characterization of human placental catechol-O-methyltransferase cDNA</article-title><source>DNA Cell Biol</source><year>1991</year><volume>10</volume><fpage>181</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">1707278</pub-id><pub-id pub-id-type="doi">10.1089/dna.1991.10.181</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tenhunen</surname><given-names>J</given-names></name><name><surname>Salminen</surname><given-names>M</given-names></name><name><surname>Lundstrom</surname><given-names>K</given-names></name><name><surname>Kiviluoto</surname><given-names>T</given-names></name><name><surname>Savolainen</surname><given-names>R</given-names></name><name><surname>Ulmanen</surname><given-names>I</given-names></name></person-group><article-title>Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters</article-title><source>Eur J Biochem</source><year>1994</year><volume>223</volume><fpage>1049</fpage><lpage>1059</lpage><pub-id pub-id-type="pmid">8055944</pub-id><pub-id pub-id-type="doi">10.1111/j.1432-1033.1994.tb19083.x</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>J</given-names></name><name><surname>Shu-Leong</surname><given-names>H</given-names></name><name><surname>Tao</surname><given-names>X</given-names></name><name><surname>Lap-Ping</surname><given-names>Y</given-names></name></person-group><article-title>Distribution of catechol-O-methyltransferase expression in human central nervous system</article-title><source>Neuroreport</source><year>1998</year><volume>9</volume><fpage>2861</fpage><lpage>2864</lpage><pub-id pub-id-type="pmid">9760135</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tenhunen</surname><given-names>J</given-names></name><name><surname>Salminen</surname><given-names>M</given-names></name><name><surname>Jalanko</surname><given-names>A</given-names></name><name><surname>Ukkonen</surname><given-names>S</given-names></name><name><surname>Ulmanen</surname><given-names>I</given-names></name></person-group><article-title>Structure of the rat catechol-O-methyltransferase gene: separate promoters are used to produce mRNAs for soluble and membrane-bound forms of the enzyme</article-title><source>DNA Cell Biol</source><year>1993</year><volume>12</volume><fpage>253</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">8466648</pub-id><pub-id pub-id-type="doi">10.1089/dna.1993.12.253</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lotta</surname><given-names>T</given-names></name><name><surname>Vidgren</surname><given-names>J</given-names></name><name><surname>Tilgmann</surname><given-names>C</given-names></name><name><surname>Ulmanen</surname><given-names>I</given-names></name><name><surname>Melen</surname><given-names>K</given-names></name><name><surname>Julkunen</surname><given-names>I</given-names></name><name><surname>Taskinen</surname><given-names>J</given-names></name></person-group><article-title>Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme</article-title><source>Biochemistry</source><year>1995</year><volume>34</volume><fpage>4202</fpage><lpage>4210</lpage><pub-id pub-id-type="pmid">7703232</pub-id><pub-id pub-id-type="doi">10.1021/bi00013a008</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tunbridge</surname><given-names>EM</given-names></name><name><surname>Lane</surname><given-names>TA</given-names></name><name><surname>Harrison</surname><given-names>PJ</given-names></name></person-group><article-title>Expression of multiple catechol-o-methyltransferase (COMT) mRNA variants in human brain</article-title><source>Am J Med Genet B Neuropsychiatr Genet</source><year>2007</year><volume>144B</volume><fpage>834</fpage><lpage>839</lpage><ext-link ext-link-type="uri" xlink:href="http://www3.interscience.wiley.com/cgi-bin/fulltext/114239977/HTMLSTART"/><pub-id pub-id-type="pmid">17477346</pub-id><pub-id pub-id-type="doi">10.1002/ajmg.b.30539</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>M</given-names></name><name><surname>Weickert</surname><given-names>CS</given-names></name><name><surname>Akil</surname><given-names>M</given-names></name><name><surname>Lipska</surname><given-names>BK</given-names></name><name><surname>Hyde</surname><given-names>TM</given-names></name><name><surname>Herman</surname><given-names>MM</given-names></name><name><surname>Kleinman</surname><given-names>JE</given-names></name><name><surname>Weinberger</surname><given-names>DR</given-names></name></person-group><article-title>Catechol O-methyltransferase mRNA expression in human and rat brain: evidence for a role in cortical neuronal function</article-title><source>Neuroscience</source><year>2003</year><volume>116</volume><fpage>127</fpage><lpage>137</lpage><pub-id pub-id-type="pmid">12535946</pub-id><pub-id pub-id-type="doi">10.1016/S0306-4522(02)00556-0</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karhunen</surname><given-names>T</given-names></name><name><surname>Tilgmann</surname><given-names>C</given-names></name><name><surname>Ulmanen</surname><given-names>I</given-names></name><name><surname>Panula</surname><given-names>P</given-names></name></person-group><article-title>Catechol-O-methyltransferase (COMT) in rat brain: immunoelectron microscopic study with an antiserum against rat recombinant COMT protein</article-title><source>Neurosci Lett</source><year>1995</year><volume>187</volume><fpage>57</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">7617303</pub-id><pub-id pub-id-type="doi">10.1016/0304-3940(95)11337-V</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lundstrom</surname><given-names>K</given-names></name><name><surname>Tenhunen</surname><given-names>J</given-names></name><name><surname>Tilgmann</surname><given-names>C</given-names></name><name><surname>Karhunen</surname><given-names>T</given-names></name><name><surname>Panula</surname><given-names>P</given-names></name><name><surname>Ulmanen</surname><given-names>I</given-names></name></person-group><article-title>Cloning, expression and structure of catechol-O-methyltransferase</article-title><source>Biochim Biophys Acta</source><year>1995</year><volume>1251</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">7647086</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>GP</given-names></name><name><surname>Hartman</surname><given-names>BK</given-names></name><name><surname>Creveling</surname><given-names>CR</given-names></name></person-group><article-title>Immunohistochemical demonstration of catechol-o-methyltransferase in mammalian brain</article-title><source>Brain Res</source><year>1979</year><volume>167</volume><fpage>241</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">376064</pub-id><pub-id pub-id-type="doi">10.1016/0006-8993(79)90819-9</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sommer</surname><given-names>C</given-names></name><name><surname>Kress</surname><given-names>M</given-names></name></person-group><article-title>Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia</article-title><source>Neurosci Lett</source><year>2004</year><volume>361</volume><fpage>184</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">15135924</pub-id><pub-id pub-id-type="doi">10.1016/j.neulet.2003.12.007</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wieseler-Frank</surname><given-names>J</given-names></name><name><surname>Maier</surname><given-names>SF</given-names></name><name><surname>Watkins</surname><given-names>LR</given-names></name></person-group><article-title>Central proinflammatory cytokines and pain enhancement</article-title><source>Neurosignals</source><year>2005</year><volume>14</volume><fpage>166</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">16215299</pub-id><pub-id pub-id-type="doi">10.1159/000087655</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Leo</surname><given-names>JA</given-names></name><name><surname>Tawfik</surname><given-names>VL</given-names></name><name><surname>LaCroix-Fralish</surname><given-names>ML</given-names></name></person-group><article-title>The tetrapartite synapse: path to CNS sensitization and chronic pain</article-title><source>Pain</source><year>2006</year><volume>122</volume><fpage>17</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">16564626</pub-id><pub-id pub-id-type="doi">10.1016/j.pain.2006.02.034</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McMahon</surname><given-names>SB</given-names></name><name><surname>Cafferty</surname><given-names>WB</given-names></name><name><surname>Marchand</surname><given-names>F</given-names></name></person-group><article-title>Immune and glial cell factors as pain mediators and modulators</article-title><source>Exp Neurol</source><year>2005</year><volume>192</volume><fpage>444</fpage><lpage>462</lpage><pub-id pub-id-type="pmid">15755561</pub-id><pub-id pub-id-type="doi">10.1016/j.expneurol.2004.11.001</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Shimizu</surname><given-names>K</given-names></name><name><surname>Zou</surname><given-names>S</given-names></name><name><surname>LaGraize</surname><given-names>SC</given-names></name><name><surname>Wei</surname><given-names>F</given-names></name><name><surname>Dubner</surname><given-names>R</given-names></name><name><surname>Ren</surname><given-names>K</given-names></name></person-group><article-title>Glial-cytokine-neuronal interactions underlying the mechanisms of persistent pain</article-title><source>J Neurosci</source><year>2007</year><volume>27</volume><fpage>6006</fpage><lpage>6018</lpage><pub-id pub-id-type="pmid">17537972</pub-id><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0176-07.2007</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raghavendra</surname><given-names>V</given-names></name><name><surname>Tanga</surname><given-names>FY</given-names></name><name><surname>DeLeo</surname><given-names>JA</given-names></name></person-group><article-title>Complete Freunds adjuvant-induced peripheral inflammation evokes glial activation and proinflammatory cytokine expression in the CNS</article-title><source>Eur J Neurosci</source><year>2004</year><volume>20</volume><fpage>467</fpage><lpage>473</lpage><pub-id pub-id-type="pmid">15233755</pub-id><pub-id pub-id-type="doi">10.1111/j.1460-9568.2004.03514.x</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>XH</given-names></name><name><surname>Zang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>CY</given-names></name><name><surname>Xu</surname><given-names>JT</given-names></name><name><surname>Xin</surname><given-names>WJ</given-names></name><name><surname>Liu</surname><given-names>XG</given-names></name></person-group><article-title>Peri-sciatic administration of recombinant rat TNF-alpha induces mechanical allodynia via upregulation of TNF-alpha in dorsal root ganglia and in spinal dorsal horn: the role of NF-kappa B pathway</article-title><source>Exp Neurol</source><year>2007</year><volume>205</volume><fpage>471</fpage><lpage>484</lpage><pub-id pub-id-type="pmid">17459378</pub-id><pub-id pub-id-type="doi">10.1016/j.expneurol.2007.03.012</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shafer</surname><given-names>DM</given-names></name><name><surname>Assael</surname><given-names>L</given-names></name><name><surname>White</surname><given-names>LB</given-names></name><name><surname>Rossomando</surname><given-names>EF</given-names></name></person-group><article-title>Tumor necrosis factor-alpha as a biochemical marker of pain and outcome in temporomandibular joints with internal derangements</article-title><source>J Oral Maxillofac Surg</source><year>1994</year><volume>52</volume><fpage>786</fpage><lpage>791</lpage><comment>discussion 791&#x02013;782</comment><pub-id pub-id-type="pmid">8040729</pub-id><pub-id pub-id-type="doi">10.1016/0278-2391(94)90217-8</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tak</surname><given-names>PP</given-names></name><name><surname>Smeets</surname><given-names>TJ</given-names></name><name><surname>Daha</surname><given-names>MR</given-names></name><name><surname>Kluin</surname><given-names>PM</given-names></name><name><surname>Meijers</surname><given-names>KA</given-names></name><name><surname>Brand</surname><given-names>R</given-names></name><name><surname>Meinders</surname><given-names>AE</given-names></name><name><surname>Breedveld</surname><given-names>FC</given-names></name></person-group><article-title>Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity</article-title><source>Arthritis Rheum</source><year>1997</year><volume>40</volume><fpage>217</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">9041933</pub-id><pub-id pub-id-type="doi">10.1002/art.1780400206</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lindenlaub</surname><given-names>T</given-names></name><name><surname>Sommer</surname><given-names>C</given-names></name></person-group><article-title>Cytokines in sural nerve biopsies from inflammatory and non-inflammatory neuropathies</article-title><source>Acta Neuropathol</source><year>2003</year><volume>105</volume><fpage>593</fpage><lpage>602</lpage><pub-id pub-id-type="pmid">12734666</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname><given-names>BB</given-names></name></person-group><article-title>Signalling pathways of the TNF superfamily: a double-edged sword</article-title><source>Nat Rev Immunol</source><year>2003</year><volume>3</volume><fpage>745</fpage><lpage>756</lpage><pub-id pub-id-type="pmid">12949498</pub-id><pub-id pub-id-type="doi">10.1038/nri1184</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Goeddel</surname><given-names>DV</given-names></name></person-group><article-title>TNF-R1 signaling: a beautiful pathway</article-title><source>Science</source><year>2002</year><volume>296</volume><fpage>1634</fpage><lpage>1635</lpage><pub-id pub-id-type="pmid">12040173</pub-id><pub-id pub-id-type="doi">10.1126/science.1071924</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Makarov</surname><given-names>SS</given-names></name></person-group><article-title>NF-kappaB as a therapeutic target in chronic inflammation: recent advances</article-title><source>Mol Med Today</source><year>2000</year><volume>6</volume><fpage>441</fpage><lpage>448</lpage><pub-id pub-id-type="pmid">11074370</pub-id><pub-id pub-id-type="doi">10.1016/S1357-4310(00)01814-1</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Neill</surname><given-names>LA</given-names></name><name><surname>Kaltschmidt</surname><given-names>C</given-names></name></person-group><article-title>NF-kappa B: a crucial transcription factor for glial and neuronal cell function</article-title><source>Trends Neurosci</source><year>1997</year><volume>20</volume><fpage>252</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">9185306</pub-id><pub-id pub-id-type="doi">10.1016/S0166-2236(96)01035-1</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mattson</surname><given-names>MP</given-names></name><name><surname>Camandola</surname><given-names>S</given-names></name></person-group><article-title>NF-kappaB in neuronal plasticity and neurodegenerative disorders</article-title><source>J Clin Invest</source><year>2001</year><volume>107</volume><fpage>247</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">11160145</pub-id><pub-id pub-id-type="doi">10.1172/JCI11916</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaltschmidt</surname><given-names>B</given-names></name><name><surname>Widera</surname><given-names>D</given-names></name><name><surname>Kaltschmidt</surname><given-names>C</given-names></name></person-group><article-title>Signaling via NF-kappaB in the nervous system</article-title><source>Biochim Biophys Acta</source><year>2005</year><volume>1745</volume><fpage>287</fpage><lpage>299</lpage><pub-id pub-id-type="pmid">15993497</pub-id><pub-id pub-id-type="doi">10.1016/j.bbamcr.2005.05.009</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>Y</given-names></name><name><surname>Gaynor</surname><given-names>RB</given-names></name></person-group><article-title>IkappaB kinases: key regulators of the NF-kappaB pathway</article-title><source>Trends Biochem Sci</source><year>2004</year><volume>29</volume><fpage>72</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">15102433</pub-id><pub-id pub-id-type="doi">10.1016/j.tibs.2003.12.003</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Karin</surname><given-names>M</given-names></name></person-group><article-title>Missing pieces in the NF-kappaB puzzle</article-title><source>Cell</source><year>2002</year><volume>109</volume><fpage>S81</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">11983155</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(02)00703-1</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>CF</given-names></name><name><surname>Sun</surname><given-names>WZ</given-names></name><name><surname>Lin</surname><given-names>JK</given-names></name><name><surname>Lin-Shiau</surname><given-names>SY</given-names></name></person-group><article-title>Activation of transcription factors of nuclear factor kappa B, activator protein-1 and octamer factors in hyperalgesia</article-title><source>Eur J Pharmacol</source><year>2000</year><volume>402</volume><fpage>61</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">10940358</pub-id><pub-id pub-id-type="doi">10.1016/S0014-2999(00)00431-3</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>KM</given-names></name><name><surname>Kang</surname><given-names>BS</given-names></name><name><surname>Lee</surname><given-names>HL</given-names></name><name><surname>Son</surname><given-names>SJ</given-names></name><name><surname>Hwang</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>DS</given-names></name><name><surname>Park</surname><given-names>JS</given-names></name><name><surname>Cho</surname><given-names>HJ</given-names></name></person-group><article-title>Spinal NF-kB activation induces COX-2 upregulation and contributes to inflammatory pain hypersensitivity</article-title><source>Eur J Neurosci</source><year>2004</year><volume>19</volume><fpage>3375</fpage><lpage>3381</lpage><pub-id pub-id-type="pmid">15217394</pub-id><pub-id pub-id-type="doi">10.1111/j.0953-816X.2004.03441.x</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Bisby</surname><given-names>MA</given-names></name></person-group><article-title>Increased activation of nuclear factor kappa B in rat lumbar dorsal root ganglion neurons following partial sciatic nerve injuries</article-title><source>Brain Res</source><year>1998</year><volume>797</volume><fpage>243</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">9666140</pub-id><pub-id pub-id-type="doi">10.1016/S0006-8993(98)00380-1</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Madrigal</surname><given-names>JL</given-names></name><name><surname>Moro</surname><given-names>MA</given-names></name><name><surname>Lizasoain</surname><given-names>I</given-names></name><name><surname>Lorenzo</surname><given-names>P</given-names></name><name><surname>Castrillo</surname><given-names>A</given-names></name><name><surname>Bosca</surname><given-names>L</given-names></name><name><surname>Leza</surname><given-names>JC</given-names></name></person-group><article-title>Inducible nitric oxide synthase expression in brain cortex after acute restraint stress is regulated by nuclear factor kappaB-mediated mechanisms</article-title><source>J Neurochem</source><year>2001</year><volume>76</volume><fpage>532</fpage><lpage>538</lpage><pub-id pub-id-type="pmid">11208916</pub-id><pub-id pub-id-type="doi">10.1046/j.1471-4159.2001.00108.x</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>LC</given-names></name><name><surname>Goettl</surname><given-names>VM</given-names></name><name><surname>Madiai</surname><given-names>F</given-names></name><name><surname>Hackshaw</surname><given-names>KV</given-names></name><name><surname>Hussain</surname><given-names>SR</given-names></name></person-group><article-title>Reciprocal regulation of nuclear factor kappa B and its inhibitor ZAS3 after peripheral nerve injury</article-title><source>BMC Neurosci</source><year>2006</year><volume>7</volume><fpage>4</fpage><pub-id pub-id-type="pmid">16409637</pub-id><pub-id pub-id-type="doi">10.1186/1471-2202-7-4</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tegeder</surname><given-names>I</given-names></name><name><surname>Niederberger</surname><given-names>E</given-names></name><name><surname>Schmidt</surname><given-names>R</given-names></name><name><surname>Kunz</surname><given-names>S</given-names></name><name><surname>Guhring</surname><given-names>H</given-names></name><name><surname>Ritzeler</surname><given-names>O</given-names></name><name><surname>Michaelis</surname><given-names>M</given-names></name><name><surname>Geisslinger</surname><given-names>G</given-names></name></person-group><article-title>Specific Inhibition of IkappaB kinase reduces hyperalgesia in inflammatory and neuropathic pain models in rats</article-title><source>J Neurosci</source><year>2004</year><volume>24</volume><fpage>1637</fpage><lpage>1645</lpage><pub-id pub-id-type="pmid">14973242</pub-id><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3118-03.2004</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laughlin</surname><given-names>TM</given-names></name><name><surname>Bethea</surname><given-names>JR</given-names></name><name><surname>Yezierski</surname><given-names>RP</given-names></name><name><surname>Wilcox</surname><given-names>GL</given-names></name></person-group><article-title>Cytokine involvement in dynorphin-induced allodynia</article-title><source>Pain</source><year>2000</year><volume>84</volume><fpage>159</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">10666520</pub-id><pub-id pub-id-type="doi">10.1016/S0304-3959(99)00195-5</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meunier</surname><given-names>A</given-names></name><name><surname>Latremoliere</surname><given-names>A</given-names></name><name><surname>Dominguez</surname><given-names>E</given-names></name><name><surname>Mauborgne</surname><given-names>A</given-names></name><name><surname>Philippe</surname><given-names>S</given-names></name><name><surname>Hamon</surname><given-names>M</given-names></name><name><surname>Mallet</surname><given-names>J</given-names></name><name><surname>Benoliel</surname><given-names>JJ</given-names></name><name><surname>Pohl</surname><given-names>M</given-names></name></person-group><article-title>Lentiviral-mediated targeted NF-kappaB blockade in dorsal spinal cord glia attenuates sciatic nerve injury-induced neuropathic pain in the rat</article-title><source>Mol Ther</source><year>2007</year><volume>15</volume><fpage>687</fpage><lpage>697</lpage><pub-id pub-id-type="pmid">17299402</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brambilla</surname><given-names>R</given-names></name><name><surname>Bracchi-Ricard</surname><given-names>V</given-names></name><name><surname>Hu</surname><given-names>WH</given-names></name><name><surname>Frydel</surname><given-names>B</given-names></name><name><surname>Bramwell</surname><given-names>A</given-names></name><name><surname>Karmally</surname><given-names>S</given-names></name><name><surname>Green</surname><given-names>EJ</given-names></name><name><surname>Bethea</surname><given-names>JR</given-names></name></person-group><article-title>Inhibition of astroglial nuclear factor kappaB reduces inflammation and improves functional recovery after spinal cord injury</article-title><source>J Exp Med</source><year>2005</year><volume>202</volume><fpage>145</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">15998793</pub-id><pub-id pub-id-type="doi">10.1084/jem.20041918</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>ES</given-names></name><name><surname>Zhang</surname><given-names>YP</given-names></name><name><surname>Sagen</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>ZQ</given-names></name><name><surname>Bethea</surname><given-names>JR</given-names></name></person-group><article-title>Transgenic glial nuclear factor-kappa B inhibition decreases formalin pain in mice</article-title><source>Neuroreport</source><year>2007</year><volume>18</volume><fpage>713</fpage><lpage>717</lpage><pub-id pub-id-type="pmid">17426605</pub-id><pub-id pub-id-type="doi">10.1097/WNR.0b013e3280d9e869</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Igwe</surname><given-names>OJ</given-names></name></person-group><article-title>Modulation of peripheral inflammation in sensory ganglia by nuclear factor (kappa)B decoy oligodeoxynucleotide: involvement of SRC kinase pathway</article-title><source>Neurosci Lett</source><year>2005</year><volume>381</volume><fpage>114</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">15882800</pub-id><pub-id pub-id-type="doi">10.1016/j.neulet.2005.02.020</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>K</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Kanno</surname><given-names>T</given-names></name><name><surname>Franzoso</surname><given-names>G</given-names></name><name><surname>Siebenlist</surname><given-names>U</given-names></name></person-group><article-title>Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha</article-title><source>Proc Natl Acad Sci USA</source><year>1993</year><volume>90</volume><fpage>2532</fpage><lpage>2536</lpage><pub-id pub-id-type="pmid">8460169</pub-id><pub-id pub-id-type="doi">10.1073/pnas.90.6.2532</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>T</given-names></name><name><surname>Ho</surname><given-names>SL</given-names></name><name><surname>Ramsden</surname><given-names>D</given-names></name></person-group><article-title>Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription</article-title><source>Mol Pharmacol</source><year>1999</year><volume>56</volume><fpage>31</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">10385681</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heinemeyer</surname><given-names>T</given-names></name><name><surname>Wingender</surname><given-names>E</given-names></name><name><surname>Reuter</surname><given-names>I</given-names></name><name><surname>Hermjakob</surname><given-names>H</given-names></name><name><surname>Kel</surname><given-names>AE</given-names></name><name><surname>Kel</surname><given-names>OV</given-names></name><name><surname>Ignatieva</surname><given-names>EV</given-names></name><name><surname>Ananko</surname><given-names>EA</given-names></name><name><surname>Podkolodnaya</surname><given-names>OA</given-names></name><name><surname>Kolpakov</surname><given-names>FA</given-names></name><etal></etal></person-group><article-title>Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL</article-title><source>Nucleic Acids Res</source><year>1998</year><volume>26</volume><fpage>362</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">9399875</pub-id><pub-id pub-id-type="doi">10.1093/nar/26.1.362</pub-id></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Varfolomeev</surname><given-names>EE</given-names></name><name><surname>Ashkenazi</surname><given-names>A</given-names></name></person-group><article-title>Tumor necrosis factor: an apoptosis JuNKie?</article-title><source>Cell</source><year>2004</year><volume>116</volume><fpage>491</fpage><lpage>497</lpage><pub-id pub-id-type="pmid">14980217</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(04)00166-7</pub-id></citation></ref><ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sitcheran</surname><given-names>R</given-names></name><name><surname>Gupta</surname><given-names>P</given-names></name><name><surname>Fisher</surname><given-names>PB</given-names></name><name><surname>Baldwin</surname><given-names>AS</given-names></name></person-group><article-title>Positive and negative regulation of EAAT2 by NF-kappaB: a role for N-myc in TNFalpha-controlled repression</article-title><source>Embo J</source><year>2005</year><volume>24</volume><fpage>510</fpage><lpage>520</lpage><pub-id pub-id-type="pmid">15660126</pub-id><pub-id pub-id-type="doi">10.1038/sj.emboj.7600555</pub-id></citation></ref><ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Peedikayil</surname><given-names>J</given-names></name><name><surname>Olson</surname><given-names>GK</given-names></name><name><surname>Siebert</surname><given-names>PD</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name></person-group><article-title>Multiple transcription factor profiling by enzyme-linked immunoassay</article-title><source>Biotechniques</source><year>2002</year><volume>32</volume><fpage>1168</fpage><pub-id pub-id-type="pmid">12019791</pub-id></citation></ref><ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Xie</surname><given-names>T</given-names></name><name><surname>Ramsden</surname><given-names>DB</given-names></name><name><surname>Ho</surname><given-names>SL</given-names></name></person-group><article-title>Human catechol-O-methyltransferase down-regulation by estradiol</article-title><source>Neuropharmacology</source><year>2003</year><volume>45</volume><fpage>1011</fpage><lpage>1018</lpage><pub-id pub-id-type="pmid">14573393</pub-id><pub-id pub-id-type="doi">10.1016/S0028-3908(03)00286-7</pub-id></citation></ref><ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>M</given-names></name><name><surname>Kaneuchi</surname><given-names>M</given-names></name><name><surname>Sakuragi</surname><given-names>N</given-names></name><name><surname>Dahiya</surname><given-names>R</given-names></name></person-group><article-title>Multiple promoters of catechol-O-methyltransferase gene are selectively inactivated by CpG hypermethylation in endometrial cancer</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>3101</fpage><lpage>3106</lpage><pub-id pub-id-type="pmid">12810635</pub-id></citation></ref><ref id="B57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abdolmaleky</surname><given-names>HM</given-names></name><name><surname>Cheng</surname><given-names>KH</given-names></name><name><surname>Faraone</surname><given-names>SV</given-names></name><name><surname>Wilcox</surname><given-names>M</given-names></name><name><surname>Glatt</surname><given-names>SJ</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Smith</surname><given-names>CL</given-names></name><name><surname>Shafa</surname><given-names>R</given-names></name><name><surname>Aeali</surname><given-names>B</given-names></name><name><surname>Carnevale</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder</article-title><source>Hum Mol Genet</source><year>2006</year><volume>15</volume><fpage>3132</fpage><lpage>3145</lpage><pub-id pub-id-type="pmid">16984965</pub-id><pub-id pub-id-type="doi">10.1093/hmg/ddl253</pub-id></citation></ref><ref id="B58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Belvin</surname><given-names>MP</given-names></name><name><surname>Anderson</surname><given-names>KV</given-names></name></person-group><article-title>A conserved signaling pathway: the Drosophila toll-dorsal pathway</article-title><source>Annu Rev Cell Dev Biol</source><year>1996</year><volume>12</volume><fpage>393</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">8970732</pub-id><pub-id pub-id-type="doi">10.1146/annurev.cellbio.12.1.393</pub-id></citation></ref><ref id="B59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cinar</surname><given-names>B</given-names></name><name><surname>Yeung</surname><given-names>F</given-names></name><name><surname>Konaka</surname><given-names>H</given-names></name><name><surname>Mayo</surname><given-names>MW</given-names></name><name><surname>Freeman</surname><given-names>MR</given-names></name><name><surname>Zhau</surname><given-names>HE</given-names></name><name><surname>Chung</surname><given-names>LW</given-names></name></person-group><article-title>Identification of a negative regulatory cis-element in the enhancer core region of the prostate-specific antigen promoter: implications for intersection of androgen receptor and nuclear factor-kappaB signalling in prostate cancer cells</article-title><source>Biochem J</source><year>2004</year><volume>379</volume><fpage>421</fpage><lpage>431</lpage><pub-id pub-id-type="pmid">14715080</pub-id><pub-id pub-id-type="doi">10.1042/BJ20031661</pub-id></citation></ref><ref id="B60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ke</surname><given-names>S</given-names></name><name><surname>Rabson</surname><given-names>AB</given-names></name><name><surname>Germino</surname><given-names>JF</given-names></name><name><surname>Gallo</surname><given-names>MA</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name></person-group><article-title>Mechanism of suppression of cytochrome P-450 1A1 expression by tumor necrosis factor-alpha and lipopolysaccharide</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>39638</fpage><lpage>39644</lpage><pub-id pub-id-type="pmid">11470802</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M106286200</pub-id></citation></ref><ref id="B61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garrison</surname><given-names>CJ</given-names></name><name><surname>Dougherty</surname><given-names>PM</given-names></name><name><surname>Carlton</surname><given-names>SM</given-names></name></person-group><article-title>GFAP expression in lumbar spinal cord of naive and neuropathic rats treated with MK-801</article-title><source>Exp Neurol</source><year>1994</year><volume>129</volume><fpage>237</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">7957738</pub-id><pub-id pub-id-type="doi">10.1006/exnr.1994.1165</pub-id></citation></ref><ref id="B62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ledeboer</surname><given-names>A</given-names></name><name><surname>Gamanos</surname><given-names>M</given-names></name><name><surname>Lai</surname><given-names>W</given-names></name><name><surname>Martin</surname><given-names>D</given-names></name><name><surname>Maier</surname><given-names>SF</given-names></name><name><surname>Watkins</surname><given-names>LR</given-names></name><name><surname>Quan</surname><given-names>N</given-names></name></person-group><article-title>Involvement of spinal cord nuclear factor kappaB activation in rat models of proinflammatory cytokine-mediated pain facilitation</article-title><source>Eur J Neurosci</source><year>2005</year><volume>22</volume><fpage>1977</fpage><lpage>1986</lpage><pub-id pub-id-type="pmid">16262636</pub-id><pub-id pub-id-type="doi">10.1111/j.1460-9568.2005.04379.x</pub-id></citation></ref><ref id="B63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname><given-names>SL</given-names></name><name><surname>Young</surname><given-names>EA</given-names></name><name><surname>Hall</surname><given-names>MD</given-names></name><name><surname>McNulty</surname><given-names>S</given-names></name></person-group><article-title>Activation of astrocyte intracellular signaling pathways by interleukin-1 in rat primary striatal cultures</article-title><source>Glia</source><year>2002</year><volume>37</volume><fpage>31</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">11746781</pub-id><pub-id pub-id-type="doi">10.1002/glia.10010</pub-id></citation></ref><ref id="B64"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Srinivasan</surname><given-names>D</given-names></name><name><surname>Yen</surname><given-names>JH</given-names></name><name><surname>Joseph</surname><given-names>DJ</given-names></name><name><surname>Friedman</surname><given-names>W</given-names></name></person-group><article-title>Cell type-specific interleukin-1beta signaling in the CNS</article-title><source>J Neurosci</source><year>2004</year><volume>24</volume><fpage>6482</fpage><lpage>6488</lpage><pub-id pub-id-type="pmid">15269258</pub-id><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5712-03.2004</pub-id></citation></ref><ref id="B65"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Milligan</surname><given-names>ED</given-names></name><name><surname>Twining</surname><given-names>C</given-names></name><name><surname>Chacur</surname><given-names>M</given-names></name><name><surname>Biedenkapp</surname><given-names>J</given-names></name><name><surname>O'Connor</surname><given-names>K</given-names></name><name><surname>Poole</surname><given-names>S</given-names></name><name><surname>Tracey</surname><given-names>K</given-names></name><name><surname>Martin</surname><given-names>D</given-names></name><name><surname>Maier</surname><given-names>SF</given-names></name><name><surname>Watkins</surname><given-names>LR</given-names></name></person-group><article-title>Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats</article-title><source>J Neurosci</source><year>2003</year><volume>23</volume><fpage>1026</fpage><lpage>1040</lpage><pub-id pub-id-type="pmid">12574433</pub-id></citation></ref><ref id="B66"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roman-Blas</surname><given-names>JA</given-names></name><name><surname>Jimenez</surname><given-names>SA</given-names></name></person-group><article-title>NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis</article-title><source>Osteoarthritis Cartilage</source><year>2006</year><volume>14</volume><fpage>839</fpage><lpage>848</lpage><pub-id pub-id-type="pmid">16730463</pub-id><pub-id pub-id-type="doi">10.1016/j.joca.2006.04.008</pub-id></citation></ref><ref id="B67"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schaible</surname><given-names>HG</given-names></name><name><surname>Schmelz</surname><given-names>M</given-names></name><name><surname>Tegeder</surname><given-names>I</given-names></name></person-group><article-title>Pathophysiology and treatment of pain in joint disease</article-title><source>Adv Drug Deliv Rev</source><year>2006</year><volume>58</volume><fpage>323</fpage><lpage>342</lpage><pub-id pub-id-type="pmid">16626837</pub-id><pub-id pub-id-type="doi">10.1016/j.addr.2006.01.011</pub-id></citation></ref><ref id="B68"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Du</surname><given-names>L</given-names></name><name><surname>Kong</surname><given-names>LY</given-names></name><name><surname>Hudson</surname><given-names>PM</given-names></name><name><surname>Wilson</surname><given-names>BC</given-names></name><name><surname>Chang</surname><given-names>RC</given-names></name><name><surname>Abel</surname><given-names>HH</given-names></name><name><surname>Hong</surname><given-names>JS</given-names></name></person-group><article-title>Reduction by naloxone of lipopolysaccharide-induced neurotoxicity in mouse cortical neuron-glia co-cultures</article-title><source>Neuroscience</source><year>2000</year><volume>97</volume><fpage>749</fpage><lpage>756</lpage><pub-id pub-id-type="pmid">10842020</pub-id><pub-id pub-id-type="doi">10.1016/S0306-4522(00)00057-9</pub-id></citation></ref></ref-list></back></article> 